Why the study?
Does SM-20302 prevent carotid artery thrombosis and correlate with ex vivo platelet inhibition in heparinized versus citrated blood in a canine model?
Population
Canine model of carotid artery thrombosis induced by electrolytic injury
Comparison
SM-20302 100, 300, 600, or 1000 microg/kg i.v. vs Saline i.v.
Design
Preclinical
Follow-up
4 hours
Authors
Loading...
Supports preclinical antithrombotic testing of SM-20302; leaves open human translation pending clinical trials.
Does SM-20302 prevent carotid artery thrombosis and correlate with ex vivo platelet inhibition in heparinized versus citrated blood in a canine model?
In a canine model, the GP IIb/IIIa inhibitor SM-20302 prevented arterial thrombosis, with in vivo efficacy correlating with ex vivo platelet inhibition in heparinized but not citrated blood.
Rebello et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: